mAb Quality Control and
Analytical Development

Specialized mAb characterization, method development, and QC strategy
from early potency assay design through transfer-ready analytical packages
and BLA-stage comparability analytics.

MAB ANALYTICAL DEVELOPMENT Building Analytical Programs That
Support Development, Release, and Lifecycle

DES Pharma supports analytical development and quality control programs for monoclonal antibodies across early development, clinical manufacturing, and commercial readiness. Our teams help sponsors design analytical strategies that reflect the complexity of mAb products, including higher-order structure, charge heterogeneity, glycosylation, aggregation, fragmentation, potency, and stability. We build method packages that support both product understanding and phase-appropriate control.

Our analytical support spans physicochemical, structural, and functional characterization. That includes potency assay planning, charge variant profiling, glycan analysis, peptide mapping, intact and subunit mass analysis, aggregation assessment, and stability-indicating method development. We help teams select the right methods for the stage of development, define what must be measured as a critical quality attribute, and connect analytical work to process development, release testing, comparability, and regulatory submissions.

As programs mature, we support transfer-ready analytical packages for QC use, method qualification and validation planning, reference standard strategy, and comparability analytics for manufacturing or site changes. The goal is to build an mAb analytical program that is technically sound, clinically relevant, and practical to maintain across the product lifecycle.

mAb Characterization ScopePhysicochemical, Structural
and Functional Methods

Functional and Potency

Cell-Based Potency
Binding / ELISA
FcRn / ADCC / CDC

Structural and Identity

Peptide Mapping
Intact Mass
Subunit Analysis
HOS Assessment

Purity and Variants

icIEF
CEX-HPLC
SEC / SEC-MALS
Glycan Profiling
DLS / MFI

Stability and Degradation

Stability-Indicating Methods
Forced Degradation
Aggregation Monitoring

CQA and METHOD STRATEGY Critical Quality Attributes and
Recommended Control Methods

A useful mAb analytical strategy combines orthogonal methods to assess identity, purity, potency, structure, and stability.
Each method should answer a specific quality question and support decisions
across development, release, and lifecycle management.

FunctionalPotency
StructuralCharge Variants
StructuralGlycosylation
PurityAggregation & Particles
IdentityIdentity & Sequence
PurityProduct-Related Variants
FunctionalFc Effector Function
StabilityStability-Indicating

Potency

Recommended Methods
Cell-Based BioassayBinding AssayELISAReporter Gene Assay

Fit-for-purpose functional methods aligned with the product mechanism of action. Required for release, comparability, and ICH Q6B specifications. Method platform selected based on MOA, development stage, and QC transfer considerations.

Charge Variants

Recommended Methods
icIEFCEX-HPLCcIEF

Acidic and basic species profiling for charge heterogeneity trend assessment across process changes, stability timepoints, and comparability studies. Orthogonal platforms increase confidence for BLA-stage control.

Glycosylation

Recommended Methods
N-Glycan ProfilingGlycan MappingLectin Binding

Sialylation and fucosylation assessment linked to product consistency and Fc effector function. Critical for mAbs where glycan profile impacts ADCC activity, PK, or immunogenicity risk assessment.

Aggregation & Particles

Recommended Methods
SECSEC-MALSDLSMFINTA

Orthogonal coverage of soluble aggregates through sub-visible and visible particles. SEC as primary release method; SEC-MALS, DLS, and MFI for characterization, stability, and comparability packages per ICH Q6B and FDA particle guidance.

Identity & Sequence Confirmation

Recommended Methods
Peptide MappingIntact MassReduced MassSubunit Analysis

Sequence confirmation, disulfide mapping, and higher-order identity as required by ICH Q6B. Peptide mapping is anchor characterization; intact and subunit mass support comparability and lot release identity confirmation.

Product-Related Variants

Recommended Methods
Peptide Mapping (Ox / Deam)CEX-HPLCCE-SDS (Non-Red)

Monitoring of deamidation, oxidation, clipping, and sequence variants across stability and process development. Structural variants with potential functional impact require risk-based assessment and inclusion in comparability analytical panels.

Fc Effector Function

Recommended Methods
FcRn BindingADCC ReporterCDC AssayFcγR Binding

Applied where FcRn-mediated half-life, ADCC, CDC, or related Fc activity is relevant to the molecule's mechanism or safety profile. Assessment of glycosylation impact on Fc function is often paired with glycan profiling data.

Stability-Indicating Methods

Recommended Methods
Forced Degradation PanelSEC (Aggregation)icIEF / CEX (Charge)CE-SDS (Fragmentation)

Forced degradation study design to identify degradation pathways and confirm method sensitivity per ICH Q5C and Q2(R1). Stability-indicating methods anchor the formal stability program, shelf-life submission, and formulation comparisons.

Functional

Potency

+
Recommended Methods
Cell-Based BioassayBinding AssayELISAReporter Gene Assay

Fit-for-purpose functional methods aligned with the product mechanism of action. Required for release, comparability, and ICH Q6B specifications. Method platform selected based on MOA, development stage, and QC transfer considerations.

Structural

Charge Variants

+
Recommended Methods
icIEFCEX-HPLCcIEF

Acidic and basic species profiling for charge heterogeneity trend assessment across process changes, stability timepoints, and comparability studies. Orthogonal platforms increase confidence for BLA-stage control.

Structural

Glycosylation

+
Recommended Methods
N-Glycan ProfilingGlycan MappingLectin Binding

Sialylation and fucosylation assessment linked to product consistency and Fc effector function. Critical for mAbs where glycan profile impacts ADCC activity, PK, or immunogenicity risk assessment.

Purity

Aggregation & Particles

+
Recommended Methods
SECSEC-MALSDLSMFINTA

Orthogonal coverage of soluble aggregates through sub-visible and visible particles. SEC as primary release method; SEC-MALS, DLS, and MFI for characterization, stability, and comparability packages per ICH Q6B and FDA particle guidance.

Identity

Identity & Sequence Confirmation

+
Recommended Methods
Peptide MappingIntact MassReduced MassSubunit Analysis

Sequence confirmation, disulfide mapping, and higher-order identity as required by ICH Q6B. Peptide mapping is anchor characterization; intact and subunit mass support comparability and lot release identity confirmation.

Purity

Product-Related Variants

+
Recommended Methods
Peptide Mapping (Ox / Deam)CEX-HPLCCE-SDS (Non-Red)

Monitoring of deamidation, oxidation, clipping, and sequence variants across stability and process development. Structural variants with potential functional impact require risk-based assessment and inclusion in comparability analytical panels.

Functional

Fc Effector Function

+
Recommended Methods
FcRn BindingADCC ReporterCDC AssayFcγR Binding

Applied where FcRn-mediated half-life, ADCC, CDC, or related Fc activity is relevant to the molecule's mechanism or safety profile. Assessment of glycosylation impact on Fc function is often paired with glycan profiling data.

Stability

Stability-Indicating Methods

+
Recommended Methods
Forced Degradation PanelSEC (Aggregation)icIEF / CEX (Charge)CE-SDS (Fragmentation)

Forced degradation study design to identify degradation pathways and confirm method sensitivity per ICH Q5C and Q2(R1). Stability-indicating methods anchor the formal stability program, shelf-life submission, and formulation comparisons.

PHASE-APPROPRIATE SERVICESAnalytical Development and
Quality City Services for mAb Programs

Our analytical consulting is organized around two interconnected workstreams, the development program that generates product knowledge, and the QC infrastructure that controls it.

Method Design, Characterization and Development-Stage Analytics

Building the analytical foundation from first molecule characterization through transfer-ready method packages.

Release Testing, Method Transfer and QC Lifecycle Support

From release panel design through qualification, trending, and inspection-ready documentation.

MAB ANALYTICAL EXPERTISE Analytical Strategy
That Connects
Development to Quality Control

A strong mAb analytical package does more than describe the molecule at one point in time. It supports decisions across process development, release, stability, and comparability. DES Pharma helps sponsors build analytical programs that connect early characterization with later QC use, so methods chosen in development remain practical for qualification, transfer, and ongoing lifecycle support.

Potency and Bioassay Strategy

Cell-based, binding, and functional assay design. Platform selection for QC transfer suitability, comparability sensitivity, and regulatory acceptance calibrated to product MOA and phase expectations.

Charge and Glycan Characterization

icIEF and CEX-HPLC for charge heterogeneity, N-glycan profiling for fucosylation, sialylation, and high-mannose assessment. Orthogonal strategy for comparability and release control.

Aggregation and Particle Analysis

SEC for routine release, SEC-MALS for absolute molecular weight determination, DLS for hydrodynamic sizing, and micro-flow imaging (MFI) or nanoparticle tracking analysis (NTA) for sub-visible particle characterization in development and comparability studies.

Comparability and QC Transfer

Analytical comparability package design per ICH Q5E, selecting the right methods, defining acceptance criteria, and building documentation structures that support regulatory review and lifecycle submissions.

Why DES Pharma What We Bring to Your
mAb Analytical Program

Practical analytical chemistry and regulatory consulting applied with phase-appropriate rigor across your development lifecycle, bridging early physicochemical characterization with inspection-ready commercial Quality Control systems.

Method Selection Expertise

We know which methods work well in development and which translate into QC environments. Our recommendations balance scientific rigor with the practical constraints of qualification, transfer, and long-term use.

Development-to-QC Continuity

We build analytical programs with lifecycle in mind, ensuring characterization work informs release panel design, specification setting, and the comparability strategies that arise as programs evolve.

Regulatory-Ready Documentation

Method development reports, validation plans, and comparability analytical packages are structured for direct use in IND filings, BLA Module 3, and agency meeting packages, not for rewriting later.

Potency Assay Specialization

Potency is the most complex and highest-risk element of most mAb analytical programs. We bring specific expertise in assay design, qualification, transfer, and troubleshooting across cell-based and binding platforms.

Comparability Analytics

When processes change, analytical comparability packages need the right breadth, sensitivity, and structure. We design panels that satisfy ICH Q5E requirements and hold up to regulatory scrutiny.

CDMO and CRO Interface

We help sponsors manage analytical work across CDMOs and contract testing laboratories, from method transfer protocols and qualification acceptance criteria to oversight during execution and report review.

REGULATORY FRAMEWORK Standards and Guidance That Shape mAb Analytical Strategy

mAb analytical programs are evaluated against an interconnected set of ICH guidelines, FDA guidance documents, and compendial standards. We help sponsors understand how these apply at each stage and build programs that satisfy expectations without unnecessary complexity.

Analytical Lifecycle Milestones

Pre-IND

Characterization panel, potency platform selection, initial stability methods

Phase 1 and Phase 2

Extended ICH Q6B characterization, release panel definition, reference standard strategy

Phase 3 Pivotal

Method qualification/validation, specification setting, comparability analytics

BLA Submission and Post-Approval

Validation packages, transfer documentation, lifecycle trending, variation analytics

REGULATORY REFERENCE FRAMEWORK

ICH Q6B

Specifications for biotechnological products  anchor for CQA definition, method selection, and acceptance criteria for mAb release and characterization

ICH Q2(R1/R2)

Validation of analytical procedures governs the method validation strategy for quantitative and qualitative methods in QC and release
 

ICH Q5C

Stability testing of biotechnological products framework for stability study design, degradation pathway assessment, and shelf-life submission

ICH Q5E

Comparability of biotechnological products defines analytical comparability expectations for post-change programs and site transfers

ICH Q14

Analytical procedure development, provides modern lifecycle approach to analytical method development and ongoing performance monitoring

FDA Guidance

Development of therapeutic protein biosimilars (reference for comparability of analytical expectations) and guidance on potency tests for biological products

Get Started Build an mAb Analytical
Program That Lasts

Whether you need a phase-appropriate characterization strategy or a BLA-ready analytical package, our consultants can define the right approach for your program and stage.